ArticleFrontiers in molecular biosciences2026
Integrative analysis of cuproptosis in kidney ischemia-reperfusion injury: biomarker discovery and diagnostic model construction.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Acute kidney injury (AKI) is often associated with kidney ischemia-reperfusion injury (KIRI), which is a key driver of AKI progression. Although cuproptosis has been implicated in multiple pathological processes, its relevance to KIRI remains unclear. This study aimed to identify candidate cuproptosis-related genes associated with KIRI and characterize their potential diagnostic and biological relevance. Methods: Bioinformatic analyses of transcriptome datasets were performed to identify cuproptosis-related differentially expressed genes (CRDEGs) in KIRI. GSE43974 served as the discovery cohort, GSE126805 served as the external validation cohort, and GSE161201 was used for exploratory single-cell analysis. Focusing on these CRDEGs, we constructed a diagnostic model for KIRI using machine learning and validated it with a nomogram. Gene set enrichment analysis (GSEA), immune infiltration analysis, and correlation analyses were used to investigate signaling pathways and immune processes associated with CRDEGs. Unsupervised clustering was conducted to classify KIRI samples and characterize CRDEG-related molecular subtypes. CRDEG expression was further verified in a mouse KIRI model treated with cuproptosis modulators. Transcription factor-mRNA, miRNA-mRNA, and drug-gene interaction networks were constructed to explore potential regulatory and therapeutic associations. Results: Four CRDEGs ( Conclusion:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.